Genmab Expands use of IDBS’ ActivityBase Xtended Edition in Hybridoma Discovery
News Sep 12, 2007
IDBS has announced that Genmab BV (Utrecht, The Netherlands) has extended its use of ActivityBase Xtended Edition (ActivityBase XE) within its Hybridoma Discovery department.
Genmab initially purchased ActivityBase XE in 2006 to handle the design, capture, storage and retrieval of their plate-based screening data. Following the implementation, Genmab has more than doubled the number of ActivityBase XE licenses.
With multiple monoclonal antibody products currently in development or under evaluation to treat cancer, inflammatory conditions and infectious diseases, international biotechnology company Genmab sought a data management solution that had the flexibility to handle the data produced from the functional screening of human monoclonal antibody therapies.
ActivityBase XE enables scientists at Genmab to capture, validate and visualize the data from antibody screening in a contextually rich environment.
Arnout Gerritsen, Sr. Manager of Lead Identification at Genmab, commented: “The introduction of ActivityBase XE into our Hybridoma Discovery department has significantly improved the efficiency of our human antibody screening campaigns.
The flexibility inherent within the ActivityBase XE module enables us to use both Excel and non-Excel templates in our analysis.” He added: “Providing a context around the screening results has promoted a better understanding and enhanced decision making.”
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019